Key Highlights
- H1 2026 Revenue rose to £1.62m, but £1.40m came from a settlement with departing US partner Haleon; underlying revenue was just £0.21m.
- The board says cash lasts only until approximately October 2026 without fresh funding, and flags a material uncertainty over going concern.
- Eroxon Intense received EU and UK regulatory clearance in July 2026, with FDA clearance expected in Q4 2026.
- Female sexual health gel WSD4000 showed 78% of users reporting improved sexual function in a home-user trial.
- The European Patent Office revoked a key MED3000 patent in July 2026, though Futura is appealing and the patent remains enforceable in the interim.
Interim results: settlement flatters revenue as cash runs to October
The interim results for the six months to 30 June 2026 showed revenue of £1.62m against £1.00m in the first half of 2025. Stripping out the £1.40m Haleon settlement, underlying revenue, principally US Eroxon royalties, was just £0.21m. The operating loss narrowed to £1.20m from £6.72m, helped by the settlement and a 17% cut in pre-exceptional administrative expenses to £2.19m. The loss before tax was £1.18m (H1 2025: £6.69m) and basic loss per share was 0.20p (H1 2025: 2.17p).
Cash stood at £1.24m at 30 June 2026 and £1.06m at 31 July 2026, with the Haleon settlement received in August. The directors state that "material uncertainties exist which may cast significant doubt on the Group's ability to continue as a going concern", while preparing the accounts on a going-concern basis because funding initiatives and wider strategic Options are being pursued, with "no certainty as to the timing, terms, value or outcome".
Chief executive Alex Duggan described the half as "a period of significant strategic progress for Futura as we continued to execute our strategy, strengthen our portfolio and enhance the value of our key assets". The company also disclosed a post-period claim from a former adviser over the Haleon termination, which it disputes.
What Futura Medical does
Futura Medical (LSE:FUM) is an AIM-quoted developer of topically delivered gel formulations for sexual health. Its lead product, Eroxon (MED3000), is a drug-free gel for erectile dysfunction regulated as a medical device and sold without prescription through licensing partners: Cooper Consumer Health in the European Economic Area and the UK, and Haleon in the United States until June 2026.
Futura earns money from product supply, royalties on partner sales and, historically, milestone payments. The United States accounted for £1.61m of H1 2026 revenue, including the settlement, while EU and UK partners generated no new revenue as they sold through existing inventory. Behind Eroxon sit Eroxon Intense, a faster-acting formulation, and WSD4000, a gel platform for female sexual dysfunction, a category in which management says no regulator-approved over-the-counter treatment exists in any major market.
From £13.9m to £1.7m: the revenue reset behind the numbers
The half-year figures need to be read against a dramatic 2025. Unaudited full-year results published in April 2026 showed revenue for the year to 31 December 2025 of £1.7m, down 88% from £13.9m in 2024, when milestone payments and initial stocking orders inflated sales. The group swung from a £1.2m operating profit to a £9.1m operating loss, including £3.22m of asset impairments, with a basic loss per share of 2.78p against Earnings of 0.43p. Net Assets fell from £8.96m to £2.81m.
A trading update in September 2025 had cut 2025 revenue guidance to £1.3m to £1.4m from market expectations of about £5m. Futura raised £2.75m gross in November 2025 by placing 275 million shares at 1p, roughly 54.5% below the prior close, and cash at 31 December 2025 was £3.4m. No Dividend is paid.
Catalysts: a new US partner, Eroxon Intense and WSD4000
The most immediate change is commercial. On 29 June 2026 Futura announced that Haleon's US licence had ended early, with Haleon paying a $1.9m termination fee and transferring Marketing materials and inventory. A new distribution partner took over US commercial control on 1 September 2026, earning commission on sales while Futura controls promotional spending. Management argues this "hybrid R&D and commercial model" gives it a larger share of any future sales growth after Haleon's October 2024 launch disappointed.
Product news could follow. Eroxon Intense received EU MDR and UKCA clearance on 31 July 2026, clearing Cooper Consumer Health to launch in Europe and the UK; FDA clearance is expected in the fourth quarter of 2026, with production from the first quarter of 2027.
WSD4000 may be the larger prize. Data released in June 2026 showed 78% of 228 women in a four-week home-user test reported improved overall sexual function, and a 33-woman placebo-controlled crossover study found the gel statistically superior to placebo on arousal, genital sensation and lubrication. Futura plans a pivotal study by the end of 2026, subject to funding, targeting launch from early 2028, and says early partnering discussions have drawn initial interest. New Eroxon partners are also being sought in China, Korea, Taiwan and Turkey.
Risks: funding, dilution and a revoked European patent
Funding is the overriding risk. With £1.06m of cash at 31 July plus the £1.40m settlement receipt, the board's own runway estimate ends around October 2026. With the shares quoted at a fraction of a penny, well below the 1p placing price of last November, any further Equity raise could be heavily dilutive. The board has also referred to "wider strategic options", which could include asset sales.
Intellectual property is a second concern. On 7 July 2026 the European Patent Office's Opposition Division revoked a European patent covering MED3000. Futura is appealing and the patent remains enforceable during an appeal expected to take 18 to 24 months or longer, but an adverse final outcome would weaken European exclusivity.
Commercial execution is unproven. Underlying revenue of £0.21m in the first half shows how small Eroxon's Royalty stream has become, and the new US partner has yet to generate a sale. Eroxon Intense still needs FDA clearance, WSD4000 needs a funded pivotal trial and regulatory approval, and the disputed adviser claim adds a further, currently unquantified, uncertainty.
Outlook
Futura Medical enters the autumn with more clinical and regulatory milestones behind it than at any point since Eroxon's launch, yet less cash. Watch first for any funding announcement or strategic transaction, since the board's own timetable gives it only weeks of runway. Beyond that, the key markers are early US sell-through under the new partner, an FDA decision on Eroxon Intense in the fourth quarter, Cooper Consumer Health's European launch, and whether a partner emerges to fund the WSD4000 pivotal study. Until the financing question is answered, the pipeline's promise and the balance sheet's fragility will pull in opposite directions.






Please wait processing your request...